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skewed distribution of health care expense were used to cal-
culate adjusted mean expense for users of each product.
RESULTS: SSRI users included children and adults. Unad-
justed total paid charges were lowest for users of fluoxe-
tine. However, both the paroxetine and sertraline popula-
tions were significantly sicker as measured by the Charlson
comorbidity index (difference  0.11, p  0.05). Adjusted
for age, gender, and comorbidities, the mean paid charges
were 15% higher for paroxetine (p  .001) compared to
fluoxetine and not significantly different for sertraline
compared to fluoxetine. When total pharmacy charges are
added to the non-pharmacy charges, the paroxetine is
20% and sertraline is 27% lower than fluoxetine. Users of
paroxetine are about 50% more likely to switch among
the SSRIs. Switchers have 34% higher total charges.
CONCLUSIONS: The use of SSRIs represents an impor-
tant and growing portion of medical expense. This paper
illustrates that total medical care cost should be used in
making population-level treatment choices.
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OBJECTIVES: The Schizophrenia Care and Assessment
Program (SCAP) is a prospective observational study estab-
lished in the US and Australia to comprehensively measure
characteristics of care for schizophrenia patients in actual
clinical practice while comparing a wide range of clinical,
humanistic, and economic outcomes among older and
newer medications. A feasibility study was conducted to in-
vestigate the potential for adapting SCAP to Western Euro-
pean countries and to determine appropriate study design.
METHODS: The feasibility study was carried out in sev-
eral countries in Europe and included (1) interviews with
providers and planners of healthcare in national associa-
tions of psychiatrists, medical associations and national
and regional government (2) literature searches on a range
of aspects and outcomes of schizophrenia and (3) inter-
views to assess the key operational aspects of conducting a
SCAP study in representative clinical sites. 
RESULTS: The feasibility study indicated that a UK-SCAP
would capture the treatment and budgetary issues raised by
UK prescribers and administrators. The wide range of out-
comes assessments in SCAP (including sociodemographics,
clinical status and treatments, functional status, general
health status, quality of life, resource utilisation and carer
burden) will distinguish the study and complement data
from clinical trials. UK-SCAP will enroll approximately
600 inpatients and outpatients (limited exclusion criteria)
from late-1999 and will follow this cohort for 3 years. The
primary outcomes measurement tools will be the SCAP in-
strument, developed from items derived from established
measures and validated in the US SCAP study.
CONCLUSION: It is important to complement informa-
tion from randomized clinical trials with information from
“real life” settings. As new drug therapies have shown
promise for improved treatment of schizophrenia, more
research is needed to understand the clinical, humanistic,
and economic opportunities of these therapies.
Submitted to ECNP Conference, London, September 1999.
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Series of N-of-1 trials have long been used to help decide the
usefulness of interventions in psychology, often where con-
ventional trial designs are impractical or unethical. Recently,
N-of-1 trials have been adopted to make decisions on the
usefulness of a proven therapy in individual patients. Their
use is increasing because many people do not respond to a
proven treatment, a greater desire to individualize therapy to
enhance the risk/benefit ratio, and cost-containment pres-
sures. N-of-1 trials reduce between-subject variability. They
are useful in chronic diseases, where the effects of the active
treatment are unlikely to carry-over to the next treatment
period. N-of-1 trials provide a unique vehicle for the collec-
tion of economic data. Unlike most crossover trials, N-of-1
trials typically involve repeated episodes of the alternative
treatments being administered over consecutive cycles. This
means that each patient in a series of N-of-1 trials provides
multiple observations for each treatment considered. As the
required sample size for the economic components of clini-
cal trials have been shown to be large, such trials offer an al-
ternative to large samples that may be unfeasible. In addi-
tion, N-of-1 trials provide the means to estimate individual
cost-effectiveness ratios, which may be incorporated into the
patient, or clinician, decision making process. The problem
of follow-up must be addressed, particularly as evaluations
measuring QALYs necessarily require a life time horizon.
However, if an intermediate outcome can be identified, en-
abling extrapolation, then this problem can be addressed.
Specific examples of the use of this design will be illustrated
from the field of dementia, where the ‘number needed to
treat’ to obtain benefit in one patient is high from symptom-
atic improvement by approved cholinergic agents. The role
of economic data from N-of-1 trials to help drug develop-
ment will also be discussed.
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OBJECTIVES: To estimate the direct costs of maintaining
normal sinus rhythm (NSR) in patients with atrial fibrilla-
tion (AF) with four antiarrhythmic (AA) drugs (sotalol,
amiodarone, flecainide, and propafenone) in the Nether-
lands (NL).
METHODS: A Markov model, with a one month cycle
length and a one year treatment duration, was used to esti-
mate expected costs of maintaining NSR. An expert panel
of cardiologists was interviewed to collect data on the per-
ceived safety and efficacy of the drugs, resource use (inpa-
tient and outpatient visits, tests and procedures) for recur-
rence of AF, treatment initiation, monitoring, and side
effects. Cost data were obtained principally from the Cen-
tral Organization for Tariffs in Health Care and the Na-
tional Association of Pharmacists. Costs were estimated
separately by drugs and for patients with and without con-
comitant structural heart disease (SHD), then weighted by
the joint distribution of presence or absence of SHD, spe-
cific use of a drug in these two populations, and/or market
share of AA drugs.
RESULTS: The weighted average annual cost of maintain-
ing NSR in an AF patient was US$2,181.31. Inpatient
treatment costs, dominated mainly by costs of symptom
recurrence and therapy initiation, ranged from 78%
(flecainide) to 92% (sotalol) of total costs. Costs of moni-
toring and side effects were the highest for amiodarone
and sotalol, respectively. Drug costs, ranging from $60 for
sotalol to $252 for flecainide, were the minor contributors
to the total costs. In patients with SHD, annual costs of
maintaining NSR were $2,685 and $2,505 for sotalol and
amiodarone, the two most common drugs in the NL, re-
spectively.
CONCLUSIONS: The estimated annual cost of maintain-
ing NSR in patients with AF in the NL is as high as
US$2,685 per patient. Relatively lower AA drug costs are
offset by significant medical treatment costs, particularly
for inpatient therapy initiation and recurrence of disease
symptoms.
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OBJECTIVES: No studies to date have addressed the cost-
effectiveness of lifelong dietary treatment when adminis-
tered in “real world” community practice. This study ex-
amines whether a comprehensive intervention program to
detect and treat, through dietary therapy, hypercholester-
olemic patients is a cost-effective approach in the primary
prevention of morbidity and mortality from coronary
heart disease (CHD).
METHODS: I developed a multidimensional model of
CHD incidence using results from the Physician-Assisted
Cholesterol Education Program (PACE), a prospective
randomized trial in rural clinical practice, in combination
with multivariate logistic risk functions from the Framing-
ham Heart Study. The cost and health effects of this di-
etary intervention are projected over a lifetime for patients
with known CHD risk factors. Results were also simulated
for the pharmacologic treatment of lovastatin taken daily
in addition to dietary intervention. Changes in life expect-
ancy, quality-adjusted life expectancy, and incremental
cost-effectiveness ratios ($/QALY), were the primary out-
come measures of interest.
RESULTS: PACE participants, on average, reduced their
total serum cholesterol levels 1.3% (CI 0.43–2.14). Rela-
tive to no treatment, men on dietary treatment gained an
estimated 4 to 26 days of quality-adjusted life expectancy
at an estimated cost-effectiveness of $14,463 to $77,574
($/QALY), depending on the age of treatment initiation.
Women gained an estimated 3 to 19 days with cost-effec-
tiveness ratios from $49,998 to $102,574 ($/QALY). Rel-
ative to dietary treatment alone, the cost-effectiveness of
the combined diet-plus-lovastatin treatment ranged from
$43,620 to $49,776 ($/QALY) in men, and from $52,996
to $74,718 ($/QALY) in women.
CONCLUSIONS: Dietary intervention is a relatively cost-
effective method of CHD prevention and should remain
the preferred treatment option for younger men and
women—especially for those initially at highest risk of
CHD. Combined diet-plus-lovastatin therapy, however, is
the optimal treatment choice for older individuals and for
those who experience a reduced quality of life on stringent
dietary regimes.
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OBJECTIVES: The objective of the study was to estimate
the direct costs of maintaining normal sinus rhythm (NSR)
in patients with atrial fibrillation or flutter (AF/F) with five
antiarrhythmic (AA) agents (amiodarone, flecainide, pro-
pafenone, quinidine, sotalol).
METHODS: A Markov model was used to estimate the
expected costs of maintaining NSR in patients with AF/F
using AA therapies. Estimates of the resource utilization
(inpatient therapy initiation and monitoring, recurrence,
